Mary Kay Inc. Continues Its Support of Women’s Empowerment at the International Women’s Forum TIME’S UP Virtual Conference
19.5.2020 17:53:00 EEST | Business Wire | Press release
Mary Kay Inc. continues its support of female entrepreneurship, empowerment and thought leadership as a premier sponsor for the 2020 International Women's Forum (IWF) Virtual Cornerstone Conference. Originally scheduled to take place May 13-15, in London, the conference has shifted to a digital format due to the COVID-19 pandemic; much of the same great content and speakers will be broadcast globally in a series of virtual sessions shared weekly at https://www.iwforum.org/.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200519005709/en/
Carolyn Passey, General Manager, Mary Kay United Kingdom & Ireland (Photo: Mary Kay Inc.)
On May 21, Mary Kay will participate in a virtual session entitled “A Conversation with TIME’S UP UK” discussing important issues such as #MeToo and how the ensuing TIME’S UP movement has led to re-thinking women’s safety on film and television sets, as well as other industries around the world. Carolyn Passey, General Manager of Mary Kay UK and Ireland, will open the session focusing on changes TIME’S UP UK is seeking to implement, navigating the line between personal and professional, and aiding those who frequently find themselves vulnerable and exploited while filming.
“At Mary Kay, we advocate for women’s empowerment and gender equality and we partner with organizations whose mission is to do the same,” said Passey. “Today, as the COVID-19 crisis is exacerbating women's vulnerabilities and gender inequality1, we know trust and safety are more critical than ever for women to thrive. The workplace should be a safe and dignified place for all of us. How can we ensure—and demand—this happens? I look forward to the discussion on the topic with thought leaders from around the world.”
Speakers at the session include:
- Dame Heather Rabbatts, TIME’S UP UK Chair Managing Director of Cove Pictures; Chair of Soho Theatre and non-executive board member for Arts Alliance.
- Ita O’Brien, the UK’s leading Intimacy Coordinator and founder of Intimacy on Set, her company through which she has been developing best practices regarding intimacy and nudity in film, television and theatre and through which she trains Intimacy Coordinators all over the world.
“Now, more than ever, it is crucial to continue the conversation around safe and equal working conditions for women within the entertainment industry and beyond,” said Stephanie O’Keefe, CEO of IWF. “As the world develops a new way to work in the context of COVID-19, I am hopeful that there will be strategies in place to ensure women can re-enter the physical workplace with confidence they will be safe and treated equally. Mary Kay is a long-time supporter of gender equality, and we are thrilled to continue this fight with them to ensure a more gender-equal world.”
A link to watch the event will be available on the IWF website and its YouTube page May 26: https://www.youtube.com/channel/UCdLPNS7ai1_XHaqgEnhEjtg
1 United Nations Secretary-General’s Policy Brief on The Impact of COVID-19 on Women, April 9, 2020
https://www.un.org/sites/un2.un.org/files/policy_brief_on_covid_impact_on_women_9_apr_2020_updated.pdf
and - Blog article by United Nations Foundation, Blog article from Michelle Milford Morse and Grace Anderson, April 14, 2020
https://unfoundation.org/blog/post/shadow-pandemic-how-covid19-crisis-exacerbating-gender-inequality/
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company more than 56 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics, nutritional supplements and fragrances. Mary Kay is committed to empowering women and their families by partnering with organizations from around the world, focusing on supporting cancer research, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Mary Kay Ash’s original vision continues to shine—one lipstick at a time. Learn more at MaryKay.com.
About International Women’s Forum (IWF) and the Leadership Foundation
IWF is an invitation-only membership organization of more than 7,000 diverse and accomplished women from 33 nations on six continents. IWF advances women’s leadership and champions equality worldwide by connecting accomplished women both globally and locally. Members include Fortune 500 executives, government leaders from the local to sovereign level, international nonprofit leaders, and luminaries from the academy, arts and sciences. For more information, please visit www.iwforum.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200519005709/en/
Contact information
Mary Kay Inc. Corporate Communications
marykay.com/newsroom
972.687.5332 or media@mkcorp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
